Strata Wealth Advisors LLC Sells 3,827 Shares of Johnson & Johnson (NYSE:JNJ)

Strata Wealth Advisors LLC reduced its stake in Johnson & Johnson (NYSE:JNJ) by 64.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,100 shares of the company’s stock after selling 3,827 shares during the period. Strata Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $307,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Innealta Capital LLC bought a new position in Johnson & Johnson during the 2nd quarter valued at about $27,000. MFA Wealth Advisors LLC bought a new position in shares of Johnson & Johnson in the second quarter valued at approximately $43,000. Vermillion & White Wealth Management Group LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $44,000. Fairfield Financial Advisors LTD bought a new stake in Johnson & Johnson during the 2nd quarter worth approximately $46,000. Finally, Grayhawk Investment Strategies Inc. raised its position in Johnson & Johnson by 528.6% in the 4th quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock valued at $48,000 after purchasing an additional 259 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently issued reports on JNJ shares. Sanford C. Bernstein lifted their price target on Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Monday. Daiwa Capital Markets cut shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $160.00 to $150.00 in a research report on Tuesday, July 23rd. TD Securities reduced their price objective on Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Finally, The Goldman Sachs Group lowered their target price on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, July 19th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $173.21.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $163.21 on Tuesday. The stock has a market cap of $392.79 billion, a PE ratio of 10.18, a price-to-earnings-growth ratio of 2.71 and a beta of 0.53. The stock has a 50-day moving average of $161.58 and a 200-day moving average of $154.15. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. During the same period last year, the business posted $2.80 earnings per share. The business’s revenue for the quarter was up 4.3% compared to the same quarter last year. As a group, sell-side analysts expect that Johnson & Johnson will post 10.02 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were issued a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 annualized dividend and a dividend yield of 3.04%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.